NCT03159572 (HITOMI) is a clinical trial in Ovarian Cancer, sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan.

Who is sponsoring NCT03159572?

NCT03159572 is sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan.

What condition does NCT03159572 study?

NCT03159572 studies Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

Is NCT03159572 still recruiting?

NCT03159572 is currently completed. Last updated 21 November 2024.

Last reviewed 2024-11-21 · How we verify

NCT03159572: HITOMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations

Completed Last updated 21 November 2024

What this trial tests

trial in Ovarian Cancer in 996 participants. Completed in 16 February 2022.

Timeline

28 March 2017

Primary endpoint
16 February 2022

16 February 2022

Quick facts

Lead sponsor	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Status	Completed
Study type	OBSERVATIONAL
Enrollment	996
Start date	28 March 2017
Primary completion	16 February 2022
Estimated completion	16 February 2022
Sites	1 location across Japan

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Primary Peritoneal Cancer — all drugs for Primary Peritoneal Cancer →

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan — full company profile →

Who can join

20 and older, female only, with Ovarian Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the frequency and clinical significance of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including Fallopian tube cancer and primary peritoneal cancer).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
Takamatsu S, Yoshihara K, Baba T, Shimada M, et al · · 2023 · cited 14× · PMID 36593360 · DOI 10.1038/s41416-022-02122-9
Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study.
Yoshihara K, Baba T, Tokunaga H, Nishino K, et al · · 2023 · cited 9× · PMID 36747324 · DOI 10.1111/cas.15747
Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.
Takamatsu S, Hillman RT, Yoshihara K, Baba T, et al · · 2024 · cited 8× · PMID 39215190 · DOI 10.1038/s41416-024-02837-x
Title: AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study.
Hamada K, Hamanishi J, Ueda A, Takamatsu S, et al · · 2026 · PMID 41697393 · DOI 10.1007/s00262-026-04324-z
Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: The Japanese Gynecologic Oncology Group study JGOG3025
Yoshihara K, Baba T, Shimada M, Nishino K, et al · · 2022 · DOI 10.1101/2022.07.06.22277241

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan trials

Trials by the same sponsor.

NCT05345223 — A Registry Study on Primary/idiopathic Triglyceride Deposit Cardiomyovasculopathy · completed
NCT03461042 — The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) a · Phase 4 · completed
NCT03296826 — Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 · recruiting
NCT03282019 — Study of Long-term HFNC for COPD Patients with HOT · NA · completed
NCT02726503 — Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03159572 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Last refreshed: 21 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03159572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing